{"a":[{"_":"Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds","$":{"href":"/biotech/scribe-records-upsized-129m-ipo-latest-biotech-stock-market-debut","hreflang":"en"}}]}

IPO/OfferingPositive

AI Analysis

Summary

Scribe Therapeutics, an in vivo gene editing company, completed an upsized IPO raising $128.7 million, exceeding its initial $96 million target to fund development of lipid-lowering genetic medicines.

Outcome Details

IPO priced at $128.7 million, surpassing $96 million initial goal

Importance:6/10

Sentiment:

0.70

IPOin vivo gene editingcapital raiseupsized offering

Related Companies

$SCTX

Read the original article

Published by FierceBiotech on July 24, 2026 1:01 AM

Read Original